Olmesartan | Anti-Hypertensive | CAS#144689-24-7

MedKoo Cat#: 525777 | Name: Olmesartan

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Olmesartan is an angiotensin II receptor blocker (ARB). It works by relaxing blood vessels. This helps to lower blood pressure.

Chemical Structure

Olmesartan

CAS#144689-24-7

Theoretical Analysis

MedKoo Cat#: 525777

Name: Olmesartan

CAS#: 144689-24-7

Chemical Formula: C24H26N6O3

Exact Mass: 446.2066

Molecular Weight: 446.50

Elemental Analysis: C, 64.56; H, 5.87; N, 18.82; O, 10.75

Price and Availability

Size	Price	Availability
10mg	USD 90.00	Ready to ship
25mg	USD 180.00	Ready to ship
50mg	USD 250.00	Ready to ship
100mg	USD 400.00	2 Weeks
250mg	USD 650.00	2 Weeks

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

144689-24-7 144689-63-4 (medoxomil) 1347262-29-6 (methyl ester )

Synonym

Benicar; Olmetec; Votum; RNH-6270; RNH6270; RNH 6270; CS-866; CS866; CS 866; Olmesartan

IUPAC/Chemical Name

1-((2'-(1H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)-4-(2-hydroxypropan-2-yl)-2-propyl-1H-imidazole-5-carboxylic acid

InChi Key

VTRAEEWXHOVJFV-UHFFFAOYSA-N

InChi Code

InChI=1S/C24H26N6O3/c1-4-7-19-25-21(24(2,3)33)20(23(31)32)30(19)14-15-10-12-16(13-11-15)17-8-5-6-9-18(17)22-26-28-29-27-22/h5-6,8-13,33H,4,7,14H2,1-3H3,(H,31,32)(H,26,27,28,29)

SMILES Code

O=C(C1=C(C(C)(O)C)N=C(CCC)N1CC2=CC=C(C3=CC=CC=C3C4=NN=NN4)C=C2)O

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Product Data

Product Data

Certificate of Analysis

View CoA: current batch, Lot#T20C04I28

Safety Data Sheet (SDS)

View Safety Data Sheet (SDS)

Instruction

View handling instruction

Biological target:

Olmesartan (RNH-6270) is an angiotensin II receptor (AT1R) antagonist used to treat high blood pressure.

In vitro activity:

To determine the roles of olmesartan in endothelial cell injuries during ox-LDL exposure, cellular vitality, nitrogen monoxide (NO) and Lactate Dehydrogenase (LDH) synthesis were. The results showed ox-LDL significantly increased the LDH synthesis and decreased cell vitality and NO synthesis in neonatal rat endothelial cells (Table 1). The addition of olmesartan to ox-LDL-stimulated endothelial cells significantly alleviated all the above harmful effects, including decreased cell vitality, increased LDH secretion, upregulated p-38 MAPK and overexpression of apoptotic genes such as Caspase-3 and Bax (Figure 1). These results indicated antiapoptotic effects of olmesartan on endothelial cell injuries induced by ox-LDL in vitro. Reference: Int J Mol Sci. 2012;13(2):1512-23. https://pubmed.ncbi.nlm.nih.gov/22408405/

In vivo activity:

To determine the roles of olmesartan against ox-LDL insults in endothelial cells in vivo, mice were treated with ox-LDL (8.4 mg/kg/day), olmesartan (3 mg/kg/day) or both of them. Of course, the dose of ox-LDL at 8.4 mg/kg/day was insufficient to elevate the BP of mice. Three weeks later, it was found that BP was not significantly different among all groups of mice (Figure 2A). Interestingly, olmesartan significantly blunted the cellular injuries in terms of cell viability during the exposure of ox-LDL in vivo (Figure 2B–E). Moreover, treatment with olmesartan significantly decreased the gene expressions of Bax and Caspase-3 while increasing Bcl-2 levels in ox-LDL-treated mice. These results suggested olmesartan could protect endothelial cells against the injuries induced by ox-LDL in vivo. Reference: Int J Mol Sci. 2012;13(2):1512-23. https://pubmed.ncbi.nlm.nih.gov/22408405/

	Solvent	mg/mL	mM
Solubility
	DMSO	42.0	94.06

Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 446.50 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Formulation protocol:

1. Zhang H, Ma G, Yao Y, Qian H, Li W, Chen X, Jiang W, Zheng R. Olmesartan attenuates the impairment of endothelial cells induced by oxidized low density lipoprotein through downregulating expression of LOX-1. Int J Mol Sci. 2012;13(2):1512-23. doi: 10.3390/ijms13021512. Epub 2012 Feb 1. PMID: 22408405; PMCID: PMC3291974. 2. Zhang Y, Liang Q, Zhang Y, Hong L, Lei D, Zhang L. Olmesartan alleviates bleomycin-mediated vascular smooth muscle cell senescence via the miR-665/SDC1 axis. Am J Transl Res. 2020 Sep 15;12(9):5205-5220. PMID: 33042414; PMCID: PMC7540088. 3. Suh SH, Choi HS, Kim CS, Kim IJ, Ma SK, Scholey JW, Kim SW, Bae EH. Olmesartan Attenuates Kidney Fibrosis in a Murine Model of Alport Syndrome by Suppressing Tubular Expression of TGFβ. Int J Mol Sci. 2019 Aug 6;20(15):3843. doi: 10.3390/ijms20153843. PMID: 31390839; PMCID: PMC6695622.

In vitro protocol:

In vivo protocol:

1. Zhang H, Ma G, Yao Y, Qian H, Li W, Chen X, Jiang W, Zheng R. Olmesartan attenuates the impairment of endothelial cells induced by oxidized low density lipoprotein through downregulating expression of LOX-1. Int J Mol Sci. 2012;13(2):1512-23. doi: 10.3390/ijms13021512. Epub 2012 Feb 1. PMID: 22408405; PMCID: PMC3291974. 2. Suh SH, Choi HS, Kim CS, Kim IJ, Ma SK, Scholey JW, Kim SW, Bae EH. Olmesartan Attenuates Kidney Fibrosis in a Murine Model of Alport Syndrome by Suppressing Tubular Expression of TGFβ. Int J Mol Sci. 2019 Aug 6;20(15):3843. doi: 10.3390/ijms20153843. PMID: 31390839; PMCID: PMC6695622.

1: Sharaf El-Din AA, Abd Allah OM. Impact of Olmesartan Medoxomil on Amiodarone-Induced Pulmonary Toxicity in Rats: Focus on Transforming Growth Factor-ß1. Basic Clin Pharmacol Toxicol. 2016 Jul;119(1):58-67. doi: 10.1111/bcpt.12551. Epub 2016 Feb 5. PubMed PMID: 26781185. 2: Ianiro G, Gasbarrini A, Cammarota G. Olmesartan-associated sprue-like enteropathy: know your enemy. Scand J Gastroenterol. 2016 Jul;51(7):891. doi: 10.3109/00365521.2016.1153139. Epub 2016 Mar 22. PubMed PMID: 27001009. 3: Kourlaba G, Gialama F, Tsioufis K, Maniadakis N. A literature review to evaluate the clinical and economic value of olmesartan for the treatment of hypertensive patients. Int J Cardiol. 2016 Jun 24;221:60-74. doi: 10.1016/j.ijcard.2016.06.115. [Epub ahead of print] Review. PubMed PMID: 27404671. 4: Sezai A, Osaka S, Yaoita H, Arimoto M, Hata H, Shiono M, Sakino H. Changeover Trial of Azilsartan and Olmesartan Comparing Effects on the Renin-Angiotensin-Aldosterone System in Patients with Essential Hypertension after Cardiac Surgery (CHAOS Study). Ann Thorac Cardiovasc Surg. 2016 Jun 20;22(3):161-7. doi: 10.5761/atcs.oa.16-00054. Epub 2016 Apr 18. PubMed PMID: 27086671. 5: Tanno T, Tomita H, Narita I, Kinjo T, Nishizaki K, Ichikawa H, Kimura Y, Tanaka M, Osanai T, Okumura K. Olmesartan Inhibits Cardiac Hypertrophy in Mice Overexpressing Renin Independently of Blood Pressure: Its Beneficial Effects on ACE2/Ang(1-7)/Mas Axis and NADPH Oxidase Expression. J Cardiovasc Pharmacol. 2016 Jun;67(6):503-9. doi: 10.1097/FJC.0000000000000374. PubMed PMID: 26886190. 6: Nasr A, Gardouh A, Ghorab M. Novel Solid Self-Nanoemulsifying Drug Delivery System (S-SNEDDS) for Oral Delivery of Olmesartan Medoxomil: Design, Formulation, Pharmacokinetic and Bioavailability Evaluation. Pharmaceutics. 2016 Jun 27;8(3). pii: E20. doi: 10.3390/pharmaceutics8030020. PubMed PMID: 27355963. 7: Ruilope LM; SEVITENSION Study Investigators. Fixed-Combination Olmesartan/Amlodipine Was Superior to Perindopril + Amlodipine in Reducing Central Systolic Blood Pressure in Hypertensive Patients With Diabetes. J Clin Hypertens (Greenwich). 2016 Jun;18(6):528-35. doi: 10.1111/jch.12673. Epub 2015 Sep 23. PubMed PMID: 26395174. 8: Olmesartan: sprue-like enteropathy. Prescrire Int. 2016 May;25(171):130-1. PubMed PMID: 27280200. 9: Kamran M, Ahad A, Aqil M, Imam SS, Sultana Y, Ali A. Design, formulation and optimization of novel soft nano-carriers for transdermal olmesartan medoxomil delivery: In vitro characterization and in vivo pharmacokinetic assessment. Int J Pharm. 2016 May 30;505(1-2):147-58. doi: 10.1016/j.ijpharm.2016.03.030. Epub 2016 Mar 19. PubMed PMID: 27005906. 10: Campos Ruiz A, Urtasun Arlegui L, Marra-López Valenciano C. Sprue-like enteropathy linked to olmesartan. Rev Esp Enferm Dig. 2016 May;108(5):292-3. doi: 10.17235/reed.2016.4140/2015. PubMed PMID: 26925975. 11: Kario K, Saito I, Kushiro T, Teramukai S, Yaginuma M, Mori Y, Okuda Y, Kobayashi F, Shimada K. Persistent olmesartan-based blood pressure-lowering effects on morning hypertension in Asians: the HONEST study. Hypertens Res. 2016 May;39(5):334-41. doi: 10.1038/hr.2015.148. Epub 2016 Jan 7. PubMed PMID: 26739871; PubMed Central PMCID: PMC4865473. 12: Redon J, Pichler G; Missed Dose Study Group. Comparative Study of the Efficacy of Olmesartan/Amlodipine vs. Perindopril/Amlodipine in Peripheral and Central Blood Pressure Parameters After Missed Dose in Type 2 Diabetes. Am J Hypertens. 2016 May 24. pii: hpw033. [Epub ahead of print] PubMed PMID: 27220840. 13: White WB, Cuadra RH, Lloyd E, Bakris GL, Kupfer S. Effects of azilsartan medoxomil compared with olmesartan and valsartan on ambulatory and clinic blood pressure in patients with type 2 diabetes and prediabetes. J Hypertens. 2016 Apr;34(4):788-97. doi: 10.1097/HJH.0000000000000839. PubMed PMID: 26766564. 14: Ould Sidi Mohamed M, Colardelle P. [Enteropathy due to olmesartan]. Ann Cardiol Angeiol (Paris). 2016 Apr 26. pii: S0003-3928(16)30275-X. doi: 10.1016/j.ancard.2016.03.001. [Epub ahead of print] French. PubMed PMID: 27129872. 15: Sáez González E, Díaz Jaime FC, Del Val Antoñana A. Clinical, laboratory, serological, and histological profile of sprue-like enteropathy associated with olmesartan use. Rev Esp Enferm Dig. 2016 Apr 25;108. doi: 10.17235/reed.2016.4340/2016. [Epub ahead of print] PubMed PMID: 27109007. 16: Hammoudi N, Dior M, Giraud V, Coffin B. Olmesartan-induced enteropathy associated with cutaneous lesions. Clin Case Rep. 2016 Mar 2;4(4):379-82. doi: 10.1002/ccr3.531. eCollection 2016 Apr. PubMed PMID: 27099732; PubMed Central PMCID: PMC4831388. 17: Retraction: 'Effects of an olmesartan/amlodipine fixed dose on blood pressure control, some adipocytokines and interleukins levels compared with olmesartan or amlodipine monotherapies' by G. Derosa, A. F. G. Cicero, A. Carbone, F. Querci, E. Fogari, A. D'Angelo and P. Maffioli. J Clin Pharm Ther. 2016 Apr;41(2):237. doi: 10.1111/jcpt.12327. Epub 2016 Jan 14. PubMed PMID: 27059120. 18: Burbure N, Lebwohl B, Arguelles-Grande C, Green PH, Bhagat G, Lagana S. Olmesartan-associated sprue-like enteropathy: a systematic review with emphasis on histopathology. Hum Pathol. 2016 Apr;50:127-34. doi: 10.1016/j.humpath.2015.12.001. Epub 2015 Dec 19. PubMed PMID: 26997446. 19: Sohn IS, Kim CJ, Oh BH, Hong TJ, Park CG, Kim BS, Chung WB; Investigators. Erratum to: Efficacy and Safety Study of Olmesartan Medoxomil, Amlodipine, and Hydrochlorothiazide Combination Therapy in Patients with Hypertension Not Controlled with Olmesartan Medoxomil and Hydrochlorothiazide Combination Therapy: Results of a Randomized, Double-Blind, Multicenter Trial. Am J Cardiovasc Drugs. 2016 Apr;16(2):139. PubMed PMID: 26994003. 20: Sohn IS, Kim CJ, Oh BH, Hong TJ, Park CG, Kim BS, Chung WB; Investigators. Efficacy and Safety Study of Olmesartan Medoxomil, Amlodipine, and Hydrochlorothiazide Combination Therapy in Patients with Hypertension Not Controlled with Olmesartan Medoxomil and Hydrochlorothiazide Combination Therapy: Results of a Randomized, Double-Blind, Multicenter Trial. Am J Cardiovasc Drugs. 2016 Apr;16(2):129-38. doi: 10.1007/s40256-015-0156-x. Erratum in: Am J Cardiovasc Drugs. 2016 Apr;16(2):139. PubMed PMID: 26691333; PubMed Central PMCID: PMC4819539.